What is HIV Capsid?
Historical Background
Key Points
14 points- 1.
The capsid's primary function is to protect the HIV's RNA genome. This genetic material is fragile, and the capsid acts as a shield against enzymes and other threats within the host cell. Without this protection, the virus would be unable to replicate.
- 2.
The capsid facilitates viral entry into the host cell. It helps the virus attach to and fuse with the cell membrane, allowing the viral contents to be released inside. Think of it as a key that unlocks the door to the cell.
- 3.
After entry, the capsid is involved in transporting the viral RNA to the cell's nucleus. This is where the virus hijacks the cell's machinery to make more copies of itself. The capsid ensures the RNA reaches its destination safely.
- 4.
The capsid is made up of multiple copies of the CA protein, which assemble to form the cone-shaped structure. These proteins fit together like pieces of a puzzle, creating a strong and stable shell.
- 5.
The structure of the capsid is not rigid. It's flexible and dynamic, allowing it to change shape during different stages of the viral lifecycle. This flexibility is essential for its various functions.
- 6.
Because the capsid is essential for HIV replication, it's a prime target for antiviral drugs. Drugs that disrupt the capsid's structure or function can prevent the virus from spreading.
- 7.
One class of drugs, called capsid inhibitors, works by binding to the CA protein and preventing the capsid from assembling properly. This leads to the formation of defective capsids that cannot protect the viral RNA.
- 8.
Another approach is to develop drugs that interfere with the capsid's interactions with other cellular proteins. These interactions are necessary for viral entry and transport, so disrupting them can block the infection.
- 9.
The development of capsid inhibitors has been challenging because the capsid is a complex and dynamic structure. It requires a deep understanding of its molecular interactions.
- 10.
The first FDA-approved capsid inhibitor, lenacapavir, represents a major breakthrough in HIV treatment. It's a long-acting drug that can be administered less frequently than other HIV medications.
- 11.
Even with capsid inhibitors, HIV can develop resistance. This happens when the virus mutates, changing the structure of the capsid so that the drug can no longer bind effectively. However, recent studies suggest that the virus cannot afford to change the capsid too much, because it needs the capsid to function.
- 12.
Researchers are working to develop new capsid inhibitors that are less susceptible to resistance. This involves designing drugs that bind to different parts of the capsid or that have a different mechanism of action.
- 13.
The study of the HIV capsid has also led to a better understanding of how other viruses work. Many viruses have similar capsid structures, so insights gained from HIV research can be applied to other viral infections.
- 14.
The AAV capsid, used in gene therapy, is different from the HIV capsid. AAV capsids are used to deliver genes into cells, while HIV capsids are part of the virus itself. However, both are protein shells that protect genetic material.
Visual Insights
HIV Capsid: Structure, Function, and Drug Targets
Mind map illustrating the key aspects of the HIV capsid, its functions, and its relevance as a drug target.
HIV Capsid
- ●Structure & Composition
- ●Functions
- ●Drug Target
- ●Recent Developments
Timeline of HIV Capsid Research and Drug Development
Timeline showing the key milestones in the research and development of drugs targeting the HIV capsid.
The HIV capsid became a focus of research relatively late in the history of HIV/AIDS. The development of capsid inhibitors has been a long and challenging process.
- 1983HIV discovered
- 1990sCapsid's role in HIV lifecycle becomes clearer
- 2000sCapsid identified as a promising drug target
- 2022FDA approves lenacapavir (Sunlenca), the first capsid inhibitor
- 2025Studies focus on lenacapavir resistance mechanisms
- 2026Research on next-generation capsid inhibitors and AAV capsid engineering
Recent Developments
9 developmentsIn 2022, the FDA approved lenacapavir (Sunlenca), the first capsid inhibitor for HIV treatment, offering a new mechanism of action for patients with multi-drug resistant HIV.
Recent studies in 2025 and 2026 have focused on understanding the mechanisms of resistance to lenacapavir and developing next-generation capsid inhibitors that can overcome these resistance mutations.
Researchers are using advanced techniques like cryo-electron microscopy to visualize the HIV capsid in detail and identify new drug binding sites.
AI is being used to design new AAV capsids with enhanced multi-trait profiles, integrating protein language models with supervised fine-tuning and reinforcement learning techniques.
Finding Hope for Frizzle (FRRS1L) and Apertura Gene Therapy announced a license agreement in 2026 for the development of a gene therapy using TfR1 CapX, an AAV capsid designed to target the central nervous system.
Studies in 2025 are exploring the use of capsid inhibitors in combination with other antiviral drugs to achieve better viral suppression and prevent the emergence of resistance.
Research is ongoing to investigate the role of the capsid in HIV latency, which is a major barrier to curing HIV infection.
Scientists are exploring the potential of using the capsid as a delivery vehicle for therapeutic agents, such as gene editing tools.
New research is focusing on engineering AAV capsids to overcome limitations in tissue tropism, immune evasion, and production efficiency for gene therapy applications.